Bottom line, Stifel added that it updated its Immunova Immunovant (IMVT) reported best absolute improvements with IMVT-1402 in myasthenia gravis and chronic inflammatory demyelinating ...

The company operates through its Vant subsidiaries, including Immunovant ... including results from batoclimab’s myasthenia gravis trial, is expected in 2025. On April 22, 2025, H.C. Wainwright ...

We recently published a list of Billionaire Andreas Halvorsen’s 10 Stock Picks With Huge Upside Potential. In this article, ...

Nipocalimab (Imaavy; Johnson & Johnson), an FcRn-blocking monoclonal antibody, was approved for patients 12 years and older ...

The US Food and Drug Administration has approved nipocalimab-aahu, a new FcRn- blocking monoclonal antibody, for the ...

The FDA has approved a monoclonal antibody to treat individuals aged 12 years and older with generalized myasthenia gravis ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Nipocalimab-aahu is a human immunoglobulin G1 monoclonal antibody that binds with high affinity to the neonatal Fc receptor, resulting in the reduction of circulating IgG levels.

The U.S. FDA approval of Johnson & Johnson’s Imaavy (nipocalimab-aahu) for myasthenia gravis brings the monoclonal antibody into a treatment space that teems with competition, both approved and ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...